Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out
Elicio Therapeutics Reports Inducement Grants
Advancements in Novel Immunotherapeutics in The Oncology Battle
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
Elicio (ELTX) Q2 Loss Beats Estimates
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Elicio Therapeutics Announces Proposed Public Offering